Biofrontera (NASDAQ:BFRI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Biofrontera (NASDAQ:BFRI) from a hold rating to a buy rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Several other analysts also recently weighed in on BFRI. Weiss Ratings upgraded Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Zacks Research raised shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Biofrontera Price Performance

Shares of NASDAQ:BFRI opened at $1.36 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.78. The stock has a market cap of $20.20 million, a PE ratio of -3.02 and a beta of 0.83. The company’s fifty day moving average is $1.30 and its 200 day moving average is $1.08. Biofrontera has a 52 week low of $0.55 and a 52 week high of $1.66.

Biofrontera (NASDAQ:BFRI) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.05. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 145.81%. The business had revenue of $12.00 million during the quarter, compared to analyst estimates of $9.50 million. Research analysts anticipate that Biofrontera will post -0.6 earnings per share for the current year.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.